EW - Edwards Lifesciences Corporation
收市後：
| 前收市價 | 81.65 |
| 開市 | 81.54 |
| 買盤 | 80.35 x 900 |
| 賣出價 | 82.30 x 800 |
| 今日波幅 | 81.30 - 82.10 |
| 52 週波幅 | 67.13 - 107.92 |
| 成交量 | |
| 平均成交量 | 2,984,414 |
| 市值 | 49.716B |
| Beta 值 (5 年，每月) | 1.02 |
| 市盈率 (最近 12 個月) | 33.89 |
| 每股盈利 (最近 12 個月) | 2.42 |
| 業績公佈日 | 2023年7月26日 - 2023年7月31日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 94.20 |
Insider MonkeyEdwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call Transcript January 31, 2023 Operator: Greetings, and welcome to the Edwards Lifesciences Fourth Quarter 2022 Earnings Conference Call. Please note, this conference is being recorded. I will now turn the conference over to our host, Mark Wilterding, Senior Vice President of Investor Relations and Treasurer. Thank you. […]
BenzingaEdwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023
Edwards Lifesciences Corp (NYSE: EW) reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61. The company reported Q4 revenues of $1.35 billion, up 1% and 7% on constant currency, beating the consensus of $1.33 billion. While TAVR sales remained flat year over year, Edwards reported 1% growth for its structural heart business. It attributed that bump to its Resilia technologies launch and Mitris surgical mitral valve. Outlook: Edwards Lifesciences reaffirmed its FY23
Insider MonkeyMultiple Reasons for the Decline of Edwards Lifesciences Corporation (EW) Stock
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P […]
Insider MonkeyIs Edwards Lifesciences (EW) a Smart Long-Term Buy?
Wedgewood Partners, an investment management firm, published its fourth quarter 2022 investor letter – a copy of which can be downloaded here. A quarterly net increase of 5.2% has been recorded by the fund for the fourth quarter of 2022, below the S&P 500 Index’s 7.56% gain for the same period. Spare some time to […]
Insider Monkey10 Best 52-Week Low Stocks To Buy Now
In this article we present the list of 10 Best 52-Week Low Stocks To Buy Now. Click to skip ahead and see the 5 Best 52-Week Low Stocks To Buy Now. Microsoft Corporation (NASDAQ:MSFT), Amazon.com, Inc. (NASDAQ:AMZN), and Meta Platforms, Inc. (NASDAQ:META) are three of the biggest companies in the world that have all hit 52-week […]
InvestorPlace7 Stocks to Buy at the ‘Midterm Elections’ Bottom
Although the concept of stocks to buy at the ‘midterm elections’ bottom seems farfetched considering the broader volatility this year, the calendar might provide a change of heart. According to The New York Times, the U.S. equities sector generally follows election-related patterns. “The months leading up to midterm elections have generally been the worst in what is known as the four-year presidential election cycle. But the stock market is about to enter a sweet spot. Stocks have usually rallie
BenzingaEconomic Challenges Hit Edwards Lifesciences Q3 Earnings, Guidance Lags Wall Street Estimates
Edwards Lifesciences Corp (NYSE: EW) reported Q3 adjusted EPS of $0.61, up 13% Y/Y, missing the Wall Street consensus of $0.62. The company saw persistent U.S. hospital staffing shortages and COVID headwinds in Japan affect its TAVR sales. Edwards' TAVR sales only grew 1% Y/Y in Q3, reaching $862 million. In the U.S., Edwards' TAVR procedures increased in the mid-single digits versus the prior year. Q3 sales reached $1.32 billion, up 1% (+7% on constant currency), slightly below the consensus of
Insider MonkeyShould You Invest in Edwards Lifesciences Corporation (EW) Now
Wedgewood Partners, an investment management company, released its “Large Cap Focused Growth Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund returned -4.1% net, compared to a -4.9% return for the Standard & Poor’s Index. In addition, you can check the top 5 holdings of […]
Insider Monkey12 Best Growth Stocks to Buy According to Ray Dalio
In this article, we discuss 12 best growth stocks to buy according to Ray Dalio. If you want to see more growth stocks in Dalio’s portfolio, click 5 Best Growth Stocks to Buy According to Ray Dalio. Ray Dalio, after a 47-year successful investment career, stepped down from his role as the co-chief investment officer […]
Insider Monkey12 Best Medical Technology Stocks to Buy
In this article, we discuss 12 best medical technology stocks to buy. If you want to read about some more medical technology stocks, go directly to 5 Best Medical Technology Stocks to Buy. The medical technology industry can finally start to put the COVID-19 virus behind it after United States President Joe Biden admitted in […]
BenzingaFDA Approves Edwards Lifesciences' PASCAL Precision Transcatheter Valve Repair System For Most Frequent Cardiovascular Disorder
The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) for degenerative mitral regurgitation (DMR). TEER approximates the anterior and posterior mitral valve leaflets by grasping them with a clipping device, similar to a treatment developed in cardiac surgery called the Alfieri stitch. The PASCAL Precision system, with its grasping, atraumatic clasp and closure, and ability to elongate, enables s
Insider Monkey12 Best Medical Device Stocks To Buy Now
In this piece, we will take a look at the twelve best medical device stocks to buy now. If you want to skip our introduction to the industry and jump to the top five stocks in this list, then take a look at 5 Best Medical Device Stocks To Buy Now. The outset of the […]
BenzingaEdwards Lifesciences Shares Slide As Q2 Results Miss Expectations, Lowers FY22 Sales Outlook
Edwards Lifesciences Corp (NYSE: EW) reported second-quarter sales of $1.37 billion, flat compared to 2Q21, missing the consensus of $1.4 billion. Adjusted EPS was $0.63, which missed the consensus of $0.64. The adjusted gross profit margin was 80.5% for the quarter, compared to 75.9% in 2Q21. Transcatheter aortic valve replacement sales grew to $907 million, up 1%. Globally, the company's average selling price and market position were stable. Surgical Structural Heart sales were $229 million, d